HEPA News and Press, Hepion Pharmaceuticals Inc. From 09/01/20

Hepion Pharmaceuticals (NASDAQ: HEPA ) announces that dosing has been completed in all subjects enrolled in the Phase 1b multiple ascending dose (MAD) study of CRV431. More news on: Hepion Pharmaceuticals, Inc., Healthcare stocks news, Read more ...

EDISON, NJ / ACCESSWIRE / September 1, 2020 / Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from non-alcoholic steatohepatitis ("NASH"), today announced that CRV431 dosing...

EDISON, NJ / ACCESSWIRE / August 27, 2020 / Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) "Hepion", a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from non-alcoholic steatohepatitis ("NASH"), today announced that it wi...

Single CRV431 Administration Inhibited Hepatitis C Infection in Humanized Liver Mouse Model, with no Viral Rebound EDISON, NJ / ACCESSWIRE / August 12, 2020 / Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a biopharmaceutical company focused on the development of therapeutic drugs fo...

Amarin reports better than expected financial numbers for second quarter Amarin Corporation plc (AMRN) announced its second quarter results, and the numbers were better than anticipated. The company also provided updates about its business operations. Amarin is looking to increase the po...

Aerpio Pharmaceuticals (NASDAQ: ARPO ) +61%  on announcing a second clinical trial with funding from MTEC. More news on: Aerpio Pharmaceuticals, Inc., Whiting Petroleum Corporation, Hepion Pharmaceuticals, Inc., Stocks on the move, , Read more ...

Dosing is underway in an open-label Phase 2 clinical trial, AMBITION , evaluating Hepion Pharmaceuticals' (NASDAQ: HEPA ) lead drug CRV431 in patients with F2 (moderate fibrosis) or F3 (advanced fibrosis) nonalcoholic steatohepatitis (NASH). More news on: Hepion Pharmaceuticals, Inc....

Hepion Introduces 'AI-POWR TM ' Proprietary Big Data Analytics Platform in AMBITION Trial AI - Artificial Intelligence, using supervised and unsupervised machine learning P - Precision Medicine, individualizing treatments based on genetics, environment, and lifestyle O ...

MOGU (NYSE: MOGU ) -14% . More news on: MOGU Inc., Ascena Retail Group, Inc., Fuel Tech, Inc., Stocks on the move, , Read more ...

Gainers:  Corvus Pharmaceuticals (NASDAQ: CRVS ) +108% . More news on: Corvus Pharmaceuticals, Inc., Annovis Bio, Inc., Hepion Pharmaceuticals, Inc., Stocks on the move, , Read more ...